FrancophonIA/ELRC3.0 huggingface dataset:
English: Erleada is co-administered with a strong inhibitor of CYP3A4 (e.g., ketoconazole, ritonavir, clarithromycin) however, a reduction of the Erleada dose based on tolerability should be considered (see section 4.2).
Croatian: Nije potrebna prilagodba početne doze kada se Erleada primjenjuje istodobno sa snažnim inhibitorom CYP3A4 (npr. ketokonazolom, ritonavirom, klaritromicinom), ali potrebno je razmotriti smanjenje doze lijeka Erleada s obzirom na podnošljivost (vidjeti dio 4.2).
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL 60 mg
Croatian: NALJEPNICA BOCE 60 mg
English: • treat hayfever and allergies (e.g. fexofenadine)
Croatian: • liječenje peludne groznice i alergija (npr. feksofenadin)
English: Falls and fractures occurred in patients receiving Erleada (see section 4.8).
Croatian: U bolesnika liječenih lijekom Erleada zabilježeni su padovi i prijelomi (vidjeti dio 4.8).
English: A review of concomitant medicinal products should therefore be conducted when apalutamide treatment is initiated.
Croatian: Stoga pri uvođenju liječenja apalutamidom treba procijeniti lijekove u istodobnoj primjeni.
English: How to store Erleada
Croatian: Kako čuvati lijek Erleada
English: 24 film-coated tablets each.
Croatian: 24 filmom obložene tablete po ovitku
English: PHARMACEUTICAL FORM AND CONTENTS 120 film-coated tablets
Croatian: 120 filmom obloženih tableta
English: Each 28-day carton contains 112 film-coated tablets in 4 cardboard wallet packs of 28 film-coated tablets each.
Croatian: Jedno 28-dnevno pakiranje sadrži 112 filmom obloženih tableta u 4 kartonska ovitka, od kojih svaki sadrži 28 filmom obloženih tableta.
English: Each 30-day carton contains 120 film-coated tablets in 5 cardboard wallet packs of 24 film-coated tablets each.
Croatian: Jedno 30-dnevno pakiranje sadrži 120 filmom obloženih tableta u 5 kartonskih ovitaka, od kojih svaki sadrži 24 filmom obložene tablete.
English: However, seizures have been reported in patients taking Erleada.
Croatian: Međutim, u bolesnika koji su uzimali lijek Erleada prijavljeni su napadaji.
English: 28 film-coated tablets each.
Croatian: 28 filmom obloženih tableta po ovitku
English: How to take Erleada
Croatian: Kako uzimati lijek Erleada
English: • treat gout (e.g. colchicine)
Croatian: • liječenje gihta (npr. kolhicin)
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 60 mg (BOTTLE)
Croatian: KUTIJA 60 mg (BOCA)
English: Hypothyroidism was reported for 8.1% of patients treated with Erleada and 2.0% of patients treated with placebo based on assessments of thyroid-stimulating hormone (TSH) every 4 months.
Croatian: Temeljem vrijednosti hormona koji stimulira štitnjaču (engl. thyroid-stimulating hormone, TSH), koje su se određivale svaka 4 mjeseca, hipotireoza je prijavljena u 8,1% bolesnika liječenih lijekom Erleada i 2,0% onih koji su primali placebo.
English: • joint pain
Croatian: • padovi
English: Colloidal anhydrous silica Croscarmellose sodium Hypromellose acetate succinate Magnesium stearate Microcrystalline cellulose Microcrystalline cellulose (silicified)
Croatian: Jezgra tablete silicijev dioksid, koloidni, bezvodni karmelozanatrij, umrežena hipromelozaacetatsukcinat magnezijev stearat celuloza, mikrokristalična celuloza, mikrokristalična (silicificirana)
English: NAME OF THE MEDICINAL PRODUCT Erleada 60 mg film-coated tablets
Croatian: Erleada 60 mg filmom obložene tablete
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 60 mg (28 days)
Croatian: VANJSKI OVITAK 60 mg (28 dana)
English: Broken bones have been observed in patients taking Erleada.
Croatian: U bolesnika koji su uzimali lijek Erleada primijećeni su prijelomi kostiju.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 60 mg (30 days)
Croatian: VANJSKI OVITAK 60 mg (30 dana)
English: • treat thyroid conditions (e.g. levothyroxine)
Croatian: • liječenje bolesti štitnjače (npr. levotiroksin)
English: The side effects for Erleada include seizures.
Croatian: Nuspojave lijeka Erleada uključuju napadaje.
English: Drug transporters
Croatian: Prijenosnici lijekova
English: Age
Croatian: Lot
English: Contents of the pack and other information What Erleada contains
Croatian: Kako Erleada izgleda i sadržaj pakiranja
English: A dedicated renal impairment study for apalutamide has not been conducted.
Croatian: Nije provedeno posebno ispitivanje učinaka oštećenja bubrežne funkcije na apalutamid.
English: Male fertility is likely to be impaired by treatment with apalutamide based on findings in repeat-dose toxicology studies which were consistent with the pharmacological activity of apalutamide.
Croatian: Prema nalazima ispitivanja toksičnosti ponovljenih doza, koji su bili u skladu s farmakološkom aktivnošću apalutamida, liječenje apalutamidom vjerojatno će smanjiti plodnost muškaraca.
English: Discard unused contents appropriately in accordance with local requirements.
Croatian: Neupotrijebljene tablete potrebno je pravilno zbrinuti, sukladno lokalnim propisima.
English: • Each 28-day carton contains 112 film coated tablets in 4 cardboard wallet packs of
Croatian: • Jedno 28-dnevno pakiranje sadrži 112 filmom obloženih tableta u 4 kartonska ovitka, od kojih svaki sadrži 28 filmom obloženih tableta.
English: • broken bones
Croatian: • prijelomi kostiju
English: The elimination of apalutamide and formation of its active metabolite, N-desmethyl apalutamide, is mediated by both CYP2C8 and CYP3A4 to a similar extent at steady-state.
Croatian: N-dezmetil apalutamida posreduju u sličnoj mjeri i CYP2C8 i CYP3A4.
English: Taking Erleada
Croatian: Nuspojava i učestalost
English: • Each 30-day carton contains 120 film coated tablets in 5 cardboard wallet packs of
Croatian: • Jedno 30-dnevno pakiranje sadrži 120 filmom obloženih tableta u 5 kartonskih ovitaka, od kojih svaki sadrži 24 filmom obložene tablete.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS INNER WALLET 60 mg (28 days)
Croatian: UNUTARNJI OVITAK 60 mg (28 dana)
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each tablet contains 60 mg apalutamide.
Croatian: Jedna tableta sadrži 60 mg apalutamida.
English: No initial dose adjustment is necessary when
Croatian: OD LIJEKA, AKO JE POTREBNO
English: d.o.o.
Croatian: PRILOG I.
English: See below.
Croatian: Kroz usta.
English: MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS INNER WALLET 60 mg (30 days)
Croatian: UNUTARNJI OVITAK 60 mg (30 dana)
English: These medicines should only be used in adult women.
Croatian: Ove lijekove smiju koristiti samo odrasle ženske osobe.
English: doctor or a qualified healthcare professional should be consulted.
Croatian: liječniku ili kvalificiranom zdravstvenom radniku.
English: They should not be taken for longer than one week and if symptoms last for more than four days or worsen during the use of the medicine a
Croatian: Ne smiju se koristiti dulje od tjedan dana, a ako simptomi potraju dulje od četiri dana ili se pogoršaju tijekom primjene lijeka, potrebno je obratiti se
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom27 March 2018 EMA/181295/2018
Croatian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20. rujna 2016.
English: The HMPC conclusions only cover bearberry leaf preparations which are obtained by drying and comminuting (reducing into tiny pieces) or powdering the leaves, or by using a technique to extract compounds by putting the plant material in a solvent (such as ethanol or water) to dissolve compounds and form a liquid extract.
Croatian: Zaključcima HMPC-a obuhvaćeni su samo pripravci medvjetkinog lista koji su dobiveni sušenjem i usitnjavanjem (smanjivanjem na manje komadiće) ili usitnjavanjem lišća u prah ili primjenom tehnike za ekstrakciju spojeva stavljanjem biljnog materijala u otapalo (npr. u etanol ili vodu) radi otapanja spojeva i dobivanja tekućeg ekstrakta.
English: Bearberry leaf preparations should only be used after serious conditions have been excluded by a doctor.
Croatian: Pripravci od medvjetkinog lista smiju se koristiti samo ako je liječnik isključio ozbiljna stanja.
English: Any applications for the licensing of medicines containing bearberry leaf have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Croatian: Svi zahtjevi za odobrenje lijekova koji sadrže medvjetkin list moraju se podnijeti nacionalnim tijelima nadležnima za lijekove, koja ocjenjuju zahtjev za biljni lijek i uzimaju u obzir znanstvene zaključke HMPC-a.
English: The HMPC conclusions on the use of these bearberry leaf medicines for lower urinary tract infections are based on their ‘traditional use'.
Croatian: Zaključci HMPC-a o primjeni ovih lijekova koji sadrže medvjetkin list kod infekcija donjeg urinarnog trakta temelje se na njihovoj „tradicionalnoj primjeni”.
English: Further information on the HMPC assessment of bearberry leaf medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Croatian: Daljnje informacije o HMPC-ovoj ocjeni lijekova koji sadrže medvjetkin list, uključujući pojedinosti zaključaka Povjerenstva, mogu se pronaći pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Bearberry leaf is the common name for the leaves of the plant Arctostaphylos uva-ursi (L.) Spreng.
Croatian: Medvjetkin list je uobičajen naziv za lišće biljke Arctostaphylos uva-ursi (L.) Spreng.
English: Further information on the risks associated with these bearberry leaf medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Croatian: Više o rizicima povezanim s ovim lijekovima koji sadrže medvjetkin list, uključujući odgovarajuće mjere opreza za njihovu sigurnu primjenu, možete pronaći u monografiji pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Bearberry leaf preparations may also be found in combination with other herbal substances in some herbal medicines.
Croatian: Pripravci od medvjetkinog lista mogu postojati također i u kombinaciji s drugim biljnim tvarima u nekim biljnim lijekovima.
English: In its assessment, the HMPC considered laboratory studies which showed bearberry leaf preparations to have antibacterial action.
Croatian: Prilikom svoje ocjene HMPC je razmotrio ispitivanja provedena u laboratoriju koja su pokazala da pripravci od medvjetkinog lista imaju antibakterijsko djelovanje.
English: Herbal medicines containing these bearberry leaf preparations are usually available as herbal tea to be drunk and in liquid or solid forms to be taken by mouth.
Croatian: Biljni lijekovi koji sadrže te pripravke od medvjetkinog lista najčešće su dostupni kao biljni čaj koji se pije i u krutom obliku za uzimanje kroz usta.
English: This summary is not intended to provide practical advice on how to use medicines containing bearberry leaf.
Croatian: Svrha ovog sažetka nije davati praktične savjete o načinu primjene lijekova koji sadrže medvjetkin list.
English: Bearberry leaf EMA/181295/2018
Croatian: Medvjetkin list EMA/424828/2016
English: Women with kidney disorders must not take bearberry leaf medicines.
Croatian: Žene s poremećajima funkcije bubrega ne smiju koristiti lijekove koji sadrže medvjetkin list.
English: Information on the use and licensing of bearberry leaf medicines in EU Member States should be obtained from the relevant national authorities.
Croatian: Informacije o primjeni i davanju odobrenja za lijekove koji sadrže medvjetkin list u državama članicama EU-a mogu se dobiti od nadležnih nacionalnih tijela.
English: No clinical studies are available with preparations containing only bearberry leaf.
Croatian: Nisu dostupna klinička ispitivanja s pripravcima koji sadrže samo medvjetkin list.
English: The HMPC concluded that, on the basis of its long-standing use, these bearberry leaf preparations can be used for relief of symptoms of mild, recurrent infections in the lower urinary tract (the structure that carries urine), such as a burning sensation when passing urine and/or frequently passing urine.
Croatian: Na temelju dugotrajne primjene, HMPC je zaključio da se ovi pripravci od medvjetkinog lista mogu koristiti za liječenje simptoma blagih, opetovanih infekcija donjeg urinarnog trakta (sustava koji prenosi urin), poput osjećaja žarenja prilikom prolaska urina i/ili učestalog uriniranja.
English: Detailed instructions on how to take bearberry leaf medicines and who can use them can be found in the package leaflet that comes with the medicine.
Croatian: Detaljne upute o načinu uzimanja lijekova koji sadrže medvjetkin list i o tome tko ih smije uzimati navedene su u uputi o lijeku koja je priložena uz lijek.
English: Other information about bearberry leaf medicines
Croatian: Ostale informacije o lijekovima koji sadrže medvjetkin list
English: What is bearberry leaf?
Croatian: Što je medvjetkin list?
English: For more information about treatment with bearberry leaf medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Croatian: Za više informacija o liječenju lijekovima koji sadrže medvjetkin list pročitajte uputu o lijeku priloženu uz lijek, odnosno obratite se svom liječniku ili ljekarniku.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of bearberry leaf.
Croatian: Ovaj dokument predstavlja sažetak znanstvenih zaključaka Povjerenstva za biljne lijekove (HMPC) u pogledu medicinske primjene medvjetkinog lista.
English: What are the risks associated with bearberry leaf medicines?
Croatian: Koji su rizici povezani s lijekovima koji sadrže medvjetkin list?
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing bearberry leaf.
Croatian: Države članice EU-a uzimaju u obzir zaključke HMPCa prilikom ocjene zahtjeva za davanje odobrenja za biljne lijekove koji sadrže medvjetkin list.
English: For practical information about using bearberry leaf medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Croatian: Za praktične informacije o primjeni lijekova koji sadrže medvjetkin list bolesnici trebaju pročitati uputu o lijeku priloženu uz lijek, odnosno obratiti se svom liječniku ili ljekarniku.
English: How are bearberry leaf medicines approved in the EU?
Croatian: Kako se u EU-u odobravaju lijekovi koji sadrže medvjetkin list?
English: Bearberry leaf
Croatian: Medvjetkin list
English: What evidence supports the use of bearberry leaf medicines?
Croatian: Kojim se dokazima potkrjepljuje primjena lijekova koji sadrže medvjetkin list?
English: For dry extracts, the solvent is then evaporated.
Croatian: Otapalo se zatim uparava kako bi se dobio suhi ekstrakt.
English: Nausea, vomiting and stomach ache are side effects that have been reported with bearberry leaf medicines.
Croatian: Pri uzimanju lijekova koji sadrže medvjetkin list prijavljene su sljedeće nuspojave: mučnina, povraćanje i bol u trbuhu.
English: The full EPAR for Pegasys can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Pegasys nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The adult dose is usually 180 micrograms but the children's dose varies depending on their height and weight.
Croatian: Doza za odrasle osobe obično iznosi 180 mikrograma, ali doza za djecu ovisi o visini i tjelesnoj težini djeteta.
English: The exact way alfa interferons work in viral diseases in not fully understood, but it is thought that they act as immunomodulators (substances that modify how the immune system, the body's defence system, works).
Croatian: Točan način djelovanja alfa-interferona kod virusnih bolesti nije potpuno jasan, ali smatra se da djeluju kao imunomodulatori (tvari koje mijenjaju način djelovanja imunosnog sustava, obrambenog sustava tijela).
English: This is a summary of the European public assessment report (EPAR) for Pegasys.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) za lijek Pegasys.
English: Alfa interferons may also block the multiplication of viruses.
Croatian: Alfa-interferoni mogu također blokirati umnožavanje virusa.
English: The European Commission granted a marketing authorisation valid throughout the EU for Pegasys on 20 June 2002.
Croatian: Europska komisija izdala je odobrenje za stavljanje lijeka Pegasys u promet koje je na snazi u Europskoj uniji od 20. lipnja 2002.
English: Interferons are natural substances produced by the body that help it fight infections caused by viruses.
Croatian: Interferoni su prirodne tvari koje nastaju u tijelu i koje pomažu u borbi tijela protiv infekcija koje uzrokuju virusi.
English: Pegasys is an antiviral medicine used to treat:
Croatian: Pegasys je antivirusni lijek koji se primjenjuje u liječenju:
English: The most common side effects with Pegasys (seen in more than 1 patient in 10) are loss of appetite, headache, insomnia (difficulty sleeping), irritability, gut disorders (diarrhoea, nausea, and belly ache) rash, itching, hair loss, pain in muscles and joints, flu-like illness, reactions at the site of the injection and tiredness.
Croatian: Najčešće su nuspojave lijeka Pegasys (zabilježene u više od 1 na 10 bolesnika) gubitak apetita, glavobolja, nesanica (poteškoće sa spavanjem), iritabilnost, crijevni poremećaji (proljev, mučnina, bol u trbuhu), osip, svrbež, gubitak kose, bol u mišićima i zglobovima, bolest nalik na gripu, reakcije na mjestu injekcije i umor.
English: What measures are being taken to ensure the safe and effective use of Pegasys?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Pegasys?
English: Other information about Pegasys
Croatian: Ostale informacije o lijeku Pegasys
English: Pegasys must not be used in people who are hypersensitive (allergic) to alpha interferons or any of the other ingredients.
Croatian: Lijek Pegasys ne smije se primjenjivati u osoba koje su preosjetljive (alergične) na alfa-interferone ili bilo koje druge sastojke.
English: It is not intended to provide practical advice on how to use Pegasys.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Pegasys.
English: Pegasys is given by injection under the skin in the abdomen (belly) or thigh - once a week for 48 weeks for hepatitis B and once a week for between 16 and 72 weeks for hepatitis C.
Croatian: Lijek Pegasys daje se injekcijom pod kožu abdomena (trbuh) ili bedra, jednom tjedno tijekom 48 tjedana za liječenje hepatitisa B i jednom tjedno tijekom 16 do 72 tjedna za liječenje hepatitisa C.
English: • chronic (long-term) hepatitis B in adults and children from 3 years of age
Croatian: • kroničnog (dugotrajnog) hepatitisa B u odraslih i djece starije od 3 godine;
English: • chronic hepatitis C in adults and children from 5 years of age.
Croatian: • kroničnog hepatitisa C u odraslih i djece starije od 5 godina.
English: This decreases the rate at which interferon is removed from the body and allows the medicine to be given less often.
Croatian: To smanjuje brzinu eliminacije interferona iz tijela i omogućava rjeđu primjenu lijeka.
English: Pegasys must also not be used in patients with certain liver, heart and other conditions.
Croatian: Lijek Pegasys također se ne smije primjenjivati u bolesnika s određenim bolestima jetre, srca i drugim bolestima.
English: What is Pegasys and what is it used for?
Croatian: Što je Pegasys i za što se koristi?
English: Why is Pegasys approved?
Croatian: Zašto je Pegasys odobren?
English: Pegasys was more effective than lamivudine (another antiviral medicine) at clearing the hepatitis B virus in 2 studies of 1,372 adult patients.
Croatian: Lijek Pegasys bio je djelotvorniji od lamivudina (drugi antivirusni lijek) u uklanjanju virusa hepatitisa B u dvama ispitivanjima na 1 372 odrasla bolesnika.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pegasys have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Pegasys nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Peginterferon alfa-2a is similar to interferon alfa-2a, which is widely available in the European Union (EU) as Roferon-A.
Croatian: Peginterferon alfa-2a vrlo je sličan interferonu alfa-2a koji je dostupan u Europskoj uniji (EU) kao Roferon-A.
English: Among ‘HBeAgnegative' patients (those infected with a virus that has mutated and can be more difficult to treat), the clearance rate was 43% with Pegasys and 29% with lamivudine.
Croatian: U „HBeAgnegativnih” bolesnika (zaraženi virusom koji je mutirao i koji je ponekad teže liječiti), stopa uklanjanja lijekom Pegasys iznosila je 43 %, a lamivudinom 29 %.
English: Additional studies showed that peginterferon alfa-2a in combination with telaprevir and ribavirin or with boceprevir and ribavirin significantly increased the proportion of patients who responded to treatment compared with peginterferon alfa-2a plus ribavirin.
Croatian: Dodatna ispitivanja pokazala su da je peginterferon alfa-2a u kombinaciji s telaprevirom i ribavirinom ili s boceprevirom i ribavirinom značajno povećao udio bolesnika koji su odgovorili na liječenje u usporedbi s kombinacijom peginterferona alfa-2a i ribavirina.
English: Studies showed that Pegasys is effective at clearing signs of viral infection in adults and children with chronic hepatitis B or C. The European Medicines Agency (EMA) considered the benefits to outweigh the risks seen with this medicine and therefore recommended that it be given marketing authorisation.
Croatian: Ispitivanja su pokazala da je lijek Pegasys učinkovit u uklanjanju znakova virusne infekcije u odraslih osoba i djece s kroničnim hepatitisom B ili kroničnim hepatitisom C. Europska agencija za lijekove (EMA) zaključila je da koristi lijeka nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za stavljanje lijeka u promet.
English: What are the risks associated with Pegasys?
Croatian: Koji su rizici povezani s lijekom Pegasys?
English: Hepatitis B and C are diseases of the liver due to infection with the hepatitis B and C viruses, respectively.
Croatian: Hepatitis B i hepatitis C su bolesti jetre prouzročene infekcijom virusom hepatitisa B, odnosno virusom hepatitisa C.
English: Studies show that Pegasys is effective at clearing signs of viral infection in adults and children with chronic hepatitis B or C.
Croatian: U ispitivanjima je utvrđeno da je lijek Pegasys učinkovit u uklanjanju znakova virusne infekcije u odraslih osoba i djece s kroničnim hepatitisom B ili kroničnim hepatitisom C.
English: For more information about treatment with Pegasys, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Pegasys pročitajte u uputi o lijeku (također dio EPAR-a) odnosno obratite se svojem liječniku ili ljekarniku.
English: Three studies of 1,441 adult patients showed that more patients taking Pegasys alone had no signs of hepatitis viral activity in their blood after treatment (28 to 39%) than patients taking interferon alfa-2a (8 to 19%).
Croatian: Tri ispitivanja na 1 441 odrasla bolesnika pokazala su da veći udio bolesnika koji su primali samo lijek Pegasys nije imao znakove virusne aktivnosti hepatitisa u krvi nakon liječenja (28 do 39 %) u odnosu na bolesnike koji su primali interferon alfa-2a (8 do 19 %).